KN057
Phase 2Small molecule
KN057 is one of 62 small molecule programs targeting Hemophilia. It is currently in Phase 2.
2
Indications
4
Total Trials
3
Active Trials
61
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
93 competitors in Hemophilia a
#DrugCompanyPhaseTrials
1Hemlibra
RochePhase 3
Recombinant Human Coagulation FVIII
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3
Eptacog Alfa
Novo NordiskPhase 3
Qfitlia
GGenzyme, a Sanofi Company
Phase 3
Valoctocogene Roxaparvovec
BioMarin PharmaceuticalPhase 3
Recombinant Factor VIII
BayerPhase 3
Translarna
PPTC Therapeutics
Phase 2
Rfviia
RochePhase 3
Marstacimab
PfizerPhase 3
PF-06741086
PfizerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Efficacy and Safety2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for KN057. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SSuzhou Alphamab Co., Ltd.